

PHAR 7483 Integrated Pharmacotherapy 3 (PTX-3): Cardiology Spring 2022

Course Description

This integrated pharmacy course focuses on pathophysiology, medicinal chemistry, and pharmacology to develop therapeutic plans for patients with cardiovascular disorders.

Additional Course Information

Upon completing PTX-3, students will have developed knowledge regarding the pathophysiology, pharmacology, and pharmacotherapy of major cardiovascular disorders. Ultimately, this knowledge will allow the student to develop individualized patient care plans incorporating evidence-based principles and patient-specific factors.

Course Credit

4 credit hours

Class Meeting Days, Time & Location

Tuesday and Thursday

2:00 - 4:00 pm

W.T. Brookshire Hall Room 137

Course Coordinator

David Romerill, PharmD, BCNSP

Clinical Assistant Professor

W.T. Brookshire Hall Room 367

Phone number: 903.566.6163

Email: dromerill@uttyler.edu

Office hours: TBD

Preferred method of contact: Email

Fisch College of Pharmacy (FCOP) and UT Tyler Policies

This is part 1 of the syllabus. Part 2 contains UT Tyler and the FCOP course policies and procedures. Part 2 is available as a PDF at <https://www.uttyler.edu/pharmacy/academic-affairs/files/fcop-syllabus-policies-part2-2021.pdf>.

Required Materials

Most required course materials are available through the Robert R. Muntz Library. These materials are available either online* (<http://library.uttyler.edu/>) or on reserve at the library.

1. *Pathophysiology of Heart Disease, (6th ed). Lilly LS, ed. New York, United States: Wolters Kluwer; 2016. ISBN: 978-1-4511-9275-9. Available at: <https://ebookcentral.proquest.com/lib/uttyler/search.action?query=pathophysiology+of+heart+disease>
2. *Basic and Clinical Pharmacology (12th ed). Katzung BG, Masters SB, Trevor AJ. Lange-McGraw Hill. ISBN: 978-0-07-176401-8, 2012.
3. *Pharmacotherapy: A Pathophysiologic Approach, 9th Edition. DiPiro JT, Talbert RL, Tee GV, et al. McGraw-Hill Education. (©2014) ISBN: 978-0-07-180053-2.
4. Other required materials will be posted on the course's Canvas site.
5. Other required materials will be posted on the classes' Canvas site. The site address is [_ uttyler.edu/canvas](https://uttyler.edu/canvas).

Course Format

The course may include, but is not limited to, the following activities:

1. Independent study of selected readings
2. Individual readiness assessment tests (iRATs) and individual applications (iAPPs)
3. Team-based learning and active learning strategies:
 - a. Team readiness assessment tests (tRATs)
 - b. Team applications of content and concepts
 - c. Team presentation of content and concepts
 - d. SOAP note(s)
4. Independent preparation of reflection papers or other assignments.

Course Learning Outcomes (CLOs)

| CLOs | Related PLO(s) | Assessment Methods | Grading Method | EPA's | ACCP Std. 11 & 12 |
|--|----------------|--------------------|----------------|---|-------------------|
| 1. Integrate the principles of physiology, pathophysiology, and pharmacology into selection of appropriate medication therapy for cardiovascular disease states. | 1,2 | 1,2 | ES | 1.1, 1.2, 1.3, 1.4, 1.5, 2.1, 3.1, 3.2, 3.4, 4.1, 4.2 | - |
| 2. Predict the biochemical and cellular consequences from the pharmacology of cardiovascular drugs. | 1 | 1,2 | ES | 1.2, 3.2 | - |
| 3. Develop and recommend individualized, evidence-based therapeutic and monitoring plans based upon patient-specific factors for cardiovascular disease states. | 1,2,4,7,9 | 1,2 | ES | 1.1, 1.2, 1.3, 1.4, 1.5, 2.1, 3.1, 3.2, 3.4, 4.1, 4.2 | - |

Course Assessment Methods

| | Assessment Method | Description |
|---|---|--|
| 1 | Multiple Choice or Multiple Selection Question(s) | <i>Standard MCQ, matching, or select all that apply questions.</i> |
| 2 | Open Ended Questions | <i>Handwritten calculations, FITB, or short answer</i> |

Grading Policy & Grade Calculation

Grades will be determined based on evaluation of individual and team readiness assessment tests (iRATs, tRATs), midterm examinations, final written examinations, skills assessments, graded application assignments, participation in team-based projects, peer evaluations and other assessment methods that may include Objective Structured Clinical Examinations (OSCE). Examinations and RATs may consist of multiple-choice, true/false, short-answer, essay, and problem-based questions.

During the time the course is in progress, students whose cumulative course percentage falls below 70.0% may receive an academic alert and be subject to periodic course content review in special sessions with the course instructor(s). The student's faculty advisor may receive an academic alert to act upon on the student's behalf.

All examinations, tests, and assignments, including the final examination, may be **cumulative**. Students are responsible for material presented during the prior courses. The grading scale for all graded material is below. **The final course grade will be assigned according to the calculated percentage and the percentages will not be rounded upward or downward.**

| Standard Grade Calculation* | | | Total |
|-------------------------------------|-------------------------------|-----|-------------|
| Individual Component | iRATs/individual applications | 10% | 95% |
| | Assessment 1 | 25% | |
| | Assessment 2 | 25% | |
| | Final Exam | 35% | |
| Team Component | tRATs/team applications | 5% | 5% |
| Individual + Team Components | | | 100% |

****The final course letter grade will be determined according to the following grading scheme:***

| | |
|---|-----------------|
| A | 90 - 100 % |
| B | 80 - 89.999 % |
| C | 70 - 79.999 % |
| D | 65.0 - 69.999 % |
| F | < 65.0 % |

**PHAR 7483 Course Schedule -
Spring 2023**

| Week | Day | Topic | Instructor | CLO | WSOP Category |
|---------------------------------------|------|--|------------|-----|--------------------------------------|
| 1 | 1/10 | Course Introduction; Normal cardiac structure and function | Romerill | 1 | S01.99 |
| | 1/12 | Pathophysiology: Hypertension, Ischemic Heart Disease, ACS | Romerill | 1 | S01.01 S01.03 S01.04 S01.09 |
| 2 | 1/17 | Pharmacology: Anti-hypertensives and anti-hyperlipidemics | Romerill | 1 | S01.01 S01.08 |
| | 1/19 | Pharmacotherapy: Dyslipidemia | Snella | 3 | S01.08 |
| 3 | 1/24 | Pharmacotherapy: Hypertension | Yett | 3 | S01.01 |
| | 1/26 | Pharmacotherapy: Hypertension emergency/urgency | Yett | 3 | S01.01 S01.15 |
| 4 | 1/31 | Pharmacology: Antiplatelets/thrombolytics | Romerill | 2 | S01.03 S01.04 S01.06 |
| | 2/2 | Pharmacotherapy: Stable Ischemic Heart Disease + PAD | Snella | 3 | S01.03 S01.16 |
| 5 | 2/7 | Pharmacotherapy: Acute Coronary Syndrome (NSTEMI-ACS) | Romerill | 3 | S01.04 |
| | 2/9 | Pharmacotherapy: Acute Coronary Syndrome (STEMI-ACS) | Romerill | 3 | S01.04 |
| 6 | 2/14 | Pathophysiology: Heart Failure, Pulmonary Hypertension, Cardiomyopathy, Valve Diseases | Romerill | 1 | S01.02A S01.17 S01.18 |
| | 2/16 | Assessment 1 (Through Week 5 Friday) | All | | |
| 7 | 2/21 | Pharmacology: Vasoactive medications | Romerill | 2 | S01.07 |
| | 2/23 | Pharmacotherapy: Pulmonary Hypertension | Romerill | 3 | S01.08 |
| 8 | 2/28 | Pharmacotherapy: Chronic Heart Failure (HFrEF) | Snella | 3 | S01.02A |
| | 3/3 | Pharmacotherapy: Chronic Heart Failure (HFpEF) | Snella | 3 | S01.02A |
| 9 | 3/7 | Pharmacotherapy: Acute Decompensated Heart Failure | Romerill | 3 | S01.02B |
| | 3/9 | Pharmacology: Antiarrhythmics | Romerill | 2 | S01.05A S01.05B |
| SPRING BREAK 3/13 to 3/18/2023 | | | | | |
| 10 | 3/21 | Pharmacotherapy: Ventricular Arrhythmias | Romerill | 3 | S01.05B |
| | 3/23 | Pharmacotherapy: Supraventricular Arrhythmias | Romerill | 3 | S01.05A |
| 11 | 3/28 | Pharmacology: Anticoagulants | Romerill | 2 | S01.09 S01.06 |
| | 3/30 | Assessment 2 (Through Week 10 Friday) | All | | |
| 12 | 4/4 | Pharmacotherapy: Atrial Fibrillation Anticoagulation | Snella | 3 | S01.05A S01.06 |
| | 4/6 | Pathophysiology: Stroke | Romerill | 1 | S01.09 |
| 13 | 4/11 | Pharmacotherapy: Acute Ischemic Stroke | Romerill | 3 | S01.09 |
| | 4/13 | Pharmacotherapy: Secondary Stroke Prevention | Snella | 3 | S01.09 |
| 14 | 4/18 | Pharmacotherapy: Venous thromboembolism (Acute) | Bratteli | 3 | S01.06 |
| | 4/20 | Pharmacotherapy: Venous thromboembolism (Chronic) | Bratteli | 3 | S01.06 |
| 15 | TBD | Final Exam (Cumulative) | All | | |

Please note that dates, topics, and assignments are subject to change. In the event of a change, you will be given ample notification of the change.